27.08.2018 • News

Koch Buys into Yuhuang’s US Methanol Plant

Koch Buys into Yuhuang’s US Methanol Plant
Koch Buys into Yuhuang’s US Methanol Plant

Koch Methanol, part of Koch Industries, has taken an indirect minority stake in Yuhuang Chemical Industries’ (YCI) proposed $1.85 billion methanol plant in St. James Parish, Louisiana, USA.

Construction on the 1.7 million t/y facility started in January 2017 and commercial production is expected to begin in mid-2020. As part of the deal, Koch gets exclusive rights to the methanol offtake and will also build, own and operate a terminal for the outbound flow of material by ship, rail and truck.

Jim Sorlie, Koch Methanol’s senior vice president, said the relationship with YCI will allow Koch to continue providing a consistent and low-cost supply of methanol both in the US and in foreign markets for years to come.

“The new facility is located in a region with convenient access to natural gas, a highly skilled workforce and world-class transportation infrastructure, allowing us to be very competitive in our production and distribution. If viable, there is also sufficient land to add a second and third plant,” said Charlie Yao, YCI’s CEO. The project is supported by a syndication loan arranged and led by Bank of China.

Air Liquide said in February 2015 it had signed a long-term agreement to supply YCI with 2,400 t/d of oxygen for the methanol complex, which will use the gases group’s proprietary MegaMethanol process technology. At that time, YCI said it planned to build a second $500 million methanol plant, lifting capacity to 3.3 million t/y. A third phase could include a methanol derivatives plant.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read